DT-2216 is under clinical development by Dialectic Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DT-2216’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DT-2216 overview
DT-2216 is under development for the treatment of solid tumor and hematologic malignancy, fibrolamellar hepatocellular carcinoma, unspecified B-cell lymphomas, small-cell lung cancer and T-cell lymphoma. The drug candidate is a heterobifunctional PROTAC (proteolysis-targeting chimera), which acts by targeting VHL and BCLXL. It is administered through intravenous route and is developed using Antiapoptotic Protein Targeted Degradation (APTaD) technology.
Dialectic Therapeutics overview
Dialectic Therapeutics., is a biotechnology company that develops impactful anti-cancer drugs. The company is headquartered in United States.
For a complete picture of DT-2216’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
